Less than 10% of people who could benefit from GLP-1 drugs like Wegovy can access them, states the WHO as it releases its initial advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key barriers to universal access to the jabs that can aid individuals in losing substantial body mass, says the organization.
Weight-Loss Drug Shortage
Even under the current best projected outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – under 10% of those who need them, according to the health organization.
The advice encourages nations and manufacturers to expand access, through measures such as voluntary licensing.
A patent on the active ingredient – the core ingredient of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and boost satiety so people eat less.
Individuals typically see weight reduction after several weeks of commencing the once-weekly jabs.
Research indicates users may see weight return within a year of halting the treatment, as their typical hunger return.
Being overweight or obese increases your chance for contracting medical conditions, including diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
